Editas Medicine rises as Citi upgrades to 'buy'

Crispr Therapeutics AG

24/10/2023 16:51

** Shares of gene editing co Editas Medicine  EDIT.O  rise
5.4% to $6.59
    ** Brokerage Citi upgrades co to "buy" rating from
"neutral", citing potential for near-term share upside in two
key catalysts through the end of the year
    ** Brokerage sees potential readthrough from the upcoming
FDA advisory panel meeting of Vertex Pharmaceuticals  VRTX.O 
and CRISPR Therapeutics AG's  CRSP.BN  gene editing therapy
exa-cel
    ** The panel is scheduled to meet on Oct 31 to discuss the
therapy as a treatment of sickle cell disease (SCD), an
inherited blood disorder marked by defective hemoglobin
    ** EDIT is also developing a gene editing therapy for SCD
    ** Brokerage anticipates the updated data from EDIT's
experimental cell therapy EDIT-301 will include a meaningful
number of patients, allowing a more thorough evaluation of its
efficacy and safety profile
    ** EDIT-301 is being studied in early-stage trials in
patients with SCD and those with an inherited blood disorder
known as beta thalassemia
    ** Stock down ~26% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))